Therefore, the Keap1-Nrf2-ARE pathway may be a potential target in ovarian cancer therapy, and by inhibiting Nrf2 activity or interfering with its signalling pathway, the efficacy of chemotherapeutic agents may be improved and the resistance of tumour cells reversed [66]. Here, NFE2L2 is linked to ovarian carcinoma.